Targeted therapy in relapsed classical Hodgkin lymphoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 8, 2013, Pages 968-976

  Dinner, Shira ^a   Advani, Ranjana ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BRENTUXIMAB VEDOTIN; EVEROLIMUS; GEMCITABINE; IRATUMUMAB; LENALIDOMIDE; MOCETINOSTAT; PANOBINOSTAT; RITUXIMAB; SGN 30; VORINOSTAT;

ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLASSICAL HODGKIN LYMPHOMA; CLINICAL TRIAL; DRUG CONJUGATION; DRUG TARGETING; HUMAN; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; REED STERNBERG CELL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

ANTIGENS, CD30; DISEASE-FREE SURVIVAL; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; NEOPLASM RECURRENCE, LOCAL; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TUMOR MICROENVIRONMENT;

EID: 84882951891     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0117     Document Type: Article

References (58)

1. Horning S, Fanale M, deVos S, et al. Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort [abstract]. Ann Oncol 2008;20:Abstract 118.
2. Schmitz R, Stanelle J, Hansmann M-L, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009;4:151-174.
3. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812-1826.
4. Zheng B, Fiumara P, Li YV, et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and urvival. Blood 2003;102:1019-1027.
5. Gruss HJ, Pinto A, Gloghini A, et al. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues. Am J Pathol 1996;149:469-481.
6. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood 2008;111:1848-1854.
7. Ansell S, Horwitz S, Engert A, et al. Phase I/II study of an anti- CD30 Monoclonal Antibody (MDX-060) in Hodgkin lymphoma and anaplastic large cell lymphoma. J Clin Oncol 2007;25:2764-2769.
8. Younes A, Zalevsky J, Blum KA, et al. Evaluation of the pharmacokinetics, immunogenicity, and safety of XmAb(R)2513 in the ongoing study XmAb2513-01: a phase 1 study of every other week XmAb2513 to evaluate the safety, tolerability, and pharmacokinetics in patients with Hodgkin lymphoma or anaplastic large cell lymphoma [abstract]. Blood 2008;112:Abstract 5012.
9. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 2012;30:631-637.
10. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
11. Fanale M, Forero-Torres A, Rosenblatt J, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/ refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012;18:248-255.
12. Younes A, Gopal A, Smith S, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-2189.
13. Bartlett N, Brice P, Chen R, et al. Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 8027.
14. Ansell S, Connors J, Park S, et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin Lymphoma [abstract]. Blood 2012;120:Abstract 798
15. Clodi K, Asgari Z, Younes M, et al. Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance. Cancer 2002;94:1-5.
16. Freedman A, Kuruvilla J, Assouline SE, et al. Clinical activity of lucatumumab (HCD122) in patients (pts) with relapsed/refractory Hodgkin or non-Hodgkin lymphoma treated in a phase Ia/II clinical trial (NCT00670592) [abstract]. Blood 2010;116:Abstract 284.
17. Georgakis GV, Li Y, Humphreys R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130:501-510.
18. Georgakis GV, Li Y, Humphreys R, et al. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130:501-510.
19. Nozawa Y, Wakasa H, Abe M. Costimulatory molecules (CD80 and CD86) on Reed-Sternberg cells are associated with the proliferation of background T cells in Hodgkin's disease. Pathol Int 1998;48:10-14.
20. Smith SM, Bartlett N, Johnson L, et al. Galiximab, an anti- CD80 primatized monoclonal antibody, in relapsed Hodgkin lymphoma: final results of CALGB 50602 [abstract]. J Clin Oncol 2010;28(Suppl):Abstract 8039.
21. Strauchen JA, Breakstone BA. IL-2 receptor expression in human lymphoid lesions. Immunohistochemical study of 166 cases. Am J Pathol 1987;126:506.
22. Engert A, Diehl V, Schnell R, et al. A phase-I study of an anti- CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997;89:403-410.
23. Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001;97:250- 255.
24. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009;9:15-27.
25. Ushmorov A, Leithauser F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006;107:2493-2500.
26. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-5432.
27. Kirschbaum M, Goldman B, Zain J, et al. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 2012;53:259-262.
28. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol 2012;30:2197-2203.
29. Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011;12:1222-1228.
30. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease. Am J Pathol 1995;147:912-922.
31. Zheng B, Georgakis GV, Li Y, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factorkappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004;10:3207-3215.
32. Blum KA, Johnson JL, Niedzwiecki D, et al. Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and Leukemia Group B protocol 50206. Leuk Lymphoma 2007;48:1313-1319.
33. Trelle S, Sezer O, Naumann R, et al. Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018). Haematologica 2007;92:568-569.
34. Fanale M, Fayad L, Pro B, et al. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.Br J Haematol 2011;154:284-286.
35. Mendler J, Kelly J, Voci S, et al. Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol 2008;19:1759-1764.
36. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15:419-424.
37. Georgakis G, Li Y, Rassidakis G, et al. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;12:584-590.
38. Georgakis GV, Li Y, Rassidakis GZ, et al. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006;132:503-511.
39. Jundt F, Raetzel N, Müller C, et al. Rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-kappa B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005;106:1801-1807.
40. Johnston P, Inwards D, Colgan J, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320-324.
41. Derenzini E, Lemoine M, Buglio D, et al. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J 2011;1:e46.
42. Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012;30:4161-4167.
43. Farrell K, Jarrett RF. The molecular pathogenesis of Hodgkin lymphoma. Histopathology 2011;58:15-25.
44. Montes-Moreno S. Hodgkin's lymphomas: a tumor recognized by its microenvironment. Adv Hematol 2011;2011:142395.
45. Steidl C, Lee T, Shah S, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-885.
46. Chanan-Khan A, Chitta K, Ersing N, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol 2011;155:457-467.
47. Banerjee D. Recent advances in the pathobiology of Hodgkin's lymphoma: potential impact on diagnostic, predictive, and therapeutic strategies. Adv Hematol 2011;2011:439456.
48. Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in Hodgkin lymphoma. Blood 2009;113:5920-5926.
49. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003;98:310-314.
50. Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008;112:831-836.
51. Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 2012;119:4123-4128.
52. Kasamon Y, Jacene H, Gocke C, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012;119:4129-4132.
53. Younes A, Wong F. Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma. Ann Oncol 2009;20:1147-1148.
54. Scnell R, Dietlein M, Schomacker K, et al. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Onkologie 2008;31:49-51.
55. Fehniger T, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-5125.
56. Kuruvilla J, Taylor D, Wang L, et al. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma [abstract]. Blood 2008;112:Abstract 3052.
57. Muenst S, Hoeller S, Dirnhofer S, et al. Increased programmed death 1+ tumor infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009;40:1715-1722.
58. Juszczynski P, Ouyang J, Monti S. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007;104:13134-13139.